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Abstract 
Background: 
Primary Sjøgren`s syndrome (pSS) is a chronic autoimmune disease, characterised by 
lymphocytic infiltration of exocrine glands and autoantibody production. Fatigue is a 
frequent phenomenon in pSS, associated with reduced health-related quality of life. 
Fatigue is influenced by depressed mood, sleep disorder and autonomic dysfunction, 
but also occurs without these co-factors. Evidence from animal and human studies 
indicates that immune activation may directly influence fatigue in chronic 
inflammatory disorders.  
Sickness behaviour in animals is characterized by decreased activity, social 
withdrawal and a reduction in the intake of food and water. This behaviour is 
hypothesized to increase survival by shielding the sick animal from predators, and 
occurs automatically as a response to infection and inflammation. The pro-
inflammatory cytokine interleukin (IL)-1β is crucial for this behaviour. Fatigue in 
humans can be considered an element of sickness behaviour, and we hypothesized 
that inhibition of IL-1 would lead to a reduction in fatigue in pSS. We tested this in a 
randomized clinical trial by giving anakinra, a recombinant IL-1 receptor antagonist 
(IL-1Ra) - or placebo - to pSS patients with a high level of fatigue.   
Inflammation is closely connected with oxidative stress, and generation of reactive 
oxygen species is an important mechanism for killing of pathogens. Increased 
oxidative stress has been reported in relation to fatigue in human diseases, but has 
never been investigated in relation to fatigue in pSS. We hypothesized that pSS 
patients would have higher levels of oxidative stress than healthy controls, and that 
oxidative stress would be associated with fatigue.  
Taking oxidative stress and pro-inflammatory cytokines into consideration, some pSS 
patients are still more affected by fatigue than otherwise comparable individuals. Part 
of the explanation for this might be found in the genetic makeup of each individual 
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patient, and several recent studies point to both genetic and epigenetic factors that 
may be important for fatigue generation. Based on this, we aimed to investigate 
genetic variation in relation to fatigue in pSS.     
Main objectives:  
x Write a review article of the current knowledge of biological mechanisms      
of fatigue in inflammatory and non-inflammatory conditions. 
x Investigate the efficacy and safety of IL-1 inhibition on fatigue in pSS.   
x Investigate the plasma levels of oxidative stress markers in pSS as compared 
to healthy individuals, and further explore any association of oxidative stress 
with fatigue in pSS. 
x Investigate genetic variation, i.e., single nucleotide polymorphisms (SNP) in 
relation to fatigue in pSS.  
Subjects and methods: 
All patients included in this dissertation were recruited from the pSS patient pools at 
Stavanger University Hospital (SUS) and Haukeland University Hospital (HUS). SUS 
is the only hospital in the southern part of Rogaland County and HUS is the main 
hospital in Hordaland County, Norway.  
For the double-blind, randomised treatment trial all pSS patients in the southern part 
of Rogaland County were identified and invited to the study, and a total of 26 patients 
were eligible and agreed to participate. The patients were randomly allocated to 
treatment with either an IL-1Ra or placebo (0.9% NaCl in identical syringes), and 
self-administered the drug or the placebo by a daily subcutaneous injection. Neither 
patients nor investigators were aware of the treatment allocation. The study ran over 
four weeks. Blood was sampled and a visual analogue scale (VAS) and the Fatigue 
Severity Scale (FSS) were used to asses fatigue at the start of the study (week 0), at 
week 2, at the end of the study (week 4) and at week 5.    
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The same 26 patients were included for the plasma measures of oxidative stress. Two 
markers of protein oxidation; advanced oxidation protein products (AOPP) and 
protein carbonyl (PC), were measured in blood samples collected at week 0, before 
any interventions took place. 
For the genetic analysis we used whole blood samples from 207 pSS patients and 376 
healthy controls. We investigated the associations of fatigue and minor allele 
frequencies in 85 SNPs in 12 genes, half of which are related to mitochondrial 
function. The genes were selected based on previous studies of gene expression in the 
chronic fatigue syndrome.  
Results: 
We found that: 
x IL-1 inhibition influences fatigue in pSS as compared to placebo. We were 
not able to show this in the primary endpoint, but ad hoc analysis points to a 
strong positive effect of IL-1 inhibition on fatigue. 
x IL-1 inhibition appears to be safe in pSS. 
x Markers of protein oxidation are increased in pSS as compared to healthy 
controls. There is no association between fatigue and plasma protein 
oxidation in pSS. 
x Genetic variation in SLC25A40 and PKN1 show signals of association with 
fatigue in pSS.  
 
Conclusions:  
This dissertation strengthens the view that at least some part of fatigue has a 
biological fundament, related to inflammation. The IL-1 system is crucial in the 
development of fatigue in this setting, and IL-inhibition seems to reduce fatigue 
generation. There is a trend for association between genetic variation and fatigue in 
pSS. Fatigue is not associated with the amount of oxidised plasma proteins in pSS. 
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1. Background 
1.1 Primary Sjøgren`s syndrome 
Primary Sjøgren`s syndrome (pSS) is a systemic autoimmune exocrinopathy affecting 
0.05-0.5% of the population, women nine times more often than men (1, 2). The mean 
age for disease onset is in the fifth decade of life. The main symptoms are dry mouth 
and dry eyes – xerostomia and keratoconjunctivitis sicca – caused by a chronic 
inflammation of the salivary and lachrymal glands. Mononuclear cell infiltration in 
exocrine glands is the histopathological hallmark of pSS, and ectopic germinal centre 
formation in minor salivary glands (MSG) is seen in about one fourth of the patients 
(1, 3-5). PSS is immunologically characterised by B cell activation, 
hypergammaglobulinemia and autoantibody production against SSA/Ro- and SSB/La 
ribonucleoprotein particles. There is a small, but increased risk of B-cell lymphoma 
(3, 6). Most patients experience systemic features like fatigue, arthralgia and myalgia 
in addition to the dryness of mucous membranes. Other systemic manifestations, such 
as arthritis, Raynaud phenomena, cutaneous vasculitis, central nervous system (CNS) 
involvement and serositis, are also seen (5). Hypothyroidism is a common co-
morbidity, observed in 20-30% of the patients (5). Fatigue is an important and often 
disabling phenomenon reported by 70-80% of the patients (7, 8). It is a leading cause 
of inability to work and may lead to a reduced health related quality of life (HR-QOL) 
in this patient group (9).  
The American-European consensus group (AECG) criteria for primary and secondary 
Sjøgren`s syndrome were published in 2002 (Supplementary Table 1) (10), and are 
now widely accepted and used. It is based on two subjective and four objective 
criteria. The diagnosis of pSS requires four out of six criteria including a positive 
focus score (>50 mononuclear cells/4mm2) in MSG tissue sections and/or positive 
antibodies to anti-SSA/Ro and/or anti-SSB/La, or three out of four objective criteria. 
Secondary Sjøgren`s (sSS) syndrome requires one subjective criteria and two 
objective criteria (with the exception of autoantibodies) in a patient with an 
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established autoimmune rheumatic disease, such as rheumatoid arthritis (RA) or 
systemic lupus erythematosus (SLE).  
PSS is named after the Swedish ophthalmologist Henrik Sjögren, who first described 
the association between dry mouth, dry eyes and arthritis in 1933 (11). The lack of a 
disease activity measure has been a limitation to research in pSS. Results from 
different studies are difficult to compare due to the variety of methods used to assess 
disease severity and improvement after treatment. In this respect, the recently 
developed European League Against Rheumatism (EULAR) Sjøgren`s Syndrome 
Disease Activity Index (ESSDAI) (12) and EULAR Sjøgren`s Syndrome Patient 
Reported Index (ESSPRI) (13) hold promise for future treatment trials. 
1.2 Fatigue 
Fatigue can be defined in several ways. We use the definition “an overwhelming 
sense of tiredness, lack of energy, and feeling of exhaustion”(14). Fatigue is 
fundamentally different from normal experiences of tiredness or sleepiness, and 
patients often describe fatigue as a persistent, deep, thorough exhaustion. Fatigue is 
non-specific and highly subjective (15), which can make it difficult to evaluate and 
quantify. It is a common symptom in inflammatory and autoimmune diseases, and 
also in neurological, psychiatric and malignant disease. Fatigue affects the patients’ 
way of living, and a high level of fatigue often leads to social withdrawal, family 
conflicts and work disability. PSS and SLE patients with significant fatigue have a 
lower HR-QOL than patients without fatigue (7, 16), and fatigue interferes with 
emotional, social and physical functions. Fatigue, as other chronic disabilities, is 
costly for the society, with medical expenses, sick leave, and loss to the work force as 
the main expenses (17).  
Fatigue can be split into sub-categories such as peripheral, physical and central. 
Peripheral fatigue implies muscle fatigability due to disorders of the muscle and 
neuromuscular junction transmission (18). Physical fatigue is the somatic experience 
of exhaustion following physical efforts and is distinguishable from central fatigue. 
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Central or mental fatigue is by definition a subjective self-reported experience and 
this is the phenomenon patients usually present for evaluation (19). It is generally 
agreed that central fatigue is a complex phenomenon, difficult to describe, but there is 
no universal agreement upon whether it is appropriate to subdivide it further into 
distinct dimensions, such as emotional, cognitive and intellectual fatigue. This 
disunity becomes obvious when considering the fatigue measuring instruments; some 
are uni-dimensional, constructed to capture the “core feelings” of fatigue, while 
others are multidimensional, including items related to the intensity, variability and 
impact of fatigue. 
Recent years much attention has been paid to the chronic fatigue syndrome (CFS). 
This is a condition of unknown aetiology, characterised by unexplainable severe 
chronic fatigue and subjective complaints from several organ systems (20). It has 
been proposed that CFS is an autoimmune disease, and probable benefit from 
treatment with a B-cell depleting agent was recently shown in a small study (21). 
However, the study did not achieve the primary endpoint, and the results require 
replication and extension before a final conclusion can be drawn. 
1.2.1 Fatigue in pSS and other autoimmune diseases 
Fatigue is prevalent in pSS, and was recently reported in 85% of pSS patients, of 
whom forty percent described fatigue as their most severe symptom (7). Another 
study found “high fatigue” defined by Fatigue Severity Scale (FSS) score > 4 in 
70.7% of the pSS patients investigated (22). Mood disorders are consistently reported 
to influence fatigue, but fatigue also occurs in pSS patients who are not depressed (8, 
23). Pain, sleep disorders and learned helplessness may influence the experience of 
fatigue, in some cases accompanied by neuroendocrine disturbances and autonomic 
dysfunction (24). It is likely, but still unclear, whether there are common biological 
pathways for fatigue generation across different inflammatory somatic diseases. So 
far it has not been possible to establish a link between various “disease activity” 
markers, for example lymphocyte counts, immunoglobulin-levels or autoantibodies 
and fatigue in pSS (24, 25) or SLE (26). It is not unlikely that these markers have 
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been too broad in regard to fatigue, and that future research, mapping specific 
signalling molecules of the immune system, may detect this “missing link”. 
Several studies have reported an effect of biological drugs on fatigue, also in pSS. 
Treatment with rituximab (RTX), a chimeric murine/human anti-CD20 monoclonal 
antibody, led to a reduction in fatigue in pSS (27, 28) and CFS (21). SLE and RA 
patients who received an IL-6-blocking agent reported significant relief from fatigue 
(29, 30), and a similar effect on fatigue has been described using other biological 
agents. Examples include benefit from tumor necrosis factor (TNF)-α blocking agents 
(31) and the T-cell co-stimulation inhibitor abatacept in RA patients with fatigue (32). 
When taken together, these observations point to a strong association between pro-
inflammatory mediators and fatigue.  
1.3 The immune system 
The immune system can be considered to consist of two functionally different parts - 
the nonspecific innate immune system and the antigen-specific adaptive immune 
system (33). This division is arbitrary, as there is an intense cooperation and crosstalk 
between the two systems. The innate immune system comprises physical barriers, 
such as skin and mucosa, phagocytic cells, interferons, the complement system and 
other signalling and effector molecules. It is evolutionarily conserved in eukaryotic 
organisms from slime moulds to humans. Cells of the innate immune system rely on 
recognition of pathogen associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRR) such as the Toll-like receptors (TLR) for activation, and 
do not generate memory or persistent immunity. The innate immune system is the first 
line of defence against infection, and responds much faster than the adaptive immune 
system.  
The adaptive immune system, on the other hand, is highly differentiated. It 
compromises the B and T cells. Receptors on these cells recognise molecules that are 
“non-self” rather than specific PAMPs, and the cells of the adaptive immune system 
have the ability to generate a long lasting memory for specific pathogens (i.e. 
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immunity). Activated B-cells acquire an increased lifespan, and become 
immunoglobulin-producing plasma-cells or memory B-cells. T-cells are able to 
differentiate into several sub-populations, partly depending on the circumstances of 
activation. B and T cells specific for the same antigen must cooperate during 
activation, and there are several checkpoints both in maturation and in activation of 
the adaptive immune system to avoid unnecessary responses and autoimmunity (34).   
1.3.1 Autoimmunity 
It is generally considered that at least 5% of the population suffers from an 
autoimmune disease. The prevalence of autoimmune diseases seems to be increasing, 
not only due to reclassification of diseases or increased life span in the population 
(35). Loss of tolerance to self is a fundamental step in autoimmunity, but it is not fully 
understood how this loss of tolerance is initiated and maintained (36). It is generally 
agreed upon that autoimmunity develops due to a complex interplay between genetic 
factors, environment and chance. Autoimmune diseases are considered genetically 
complex, meaning that the combination of several genetic variants in one individual 
contribute to disease development (polygenic disease). This contrasts the Mendelian 
disorders, in which a single gene variant (mutation) is the cause of a specific disease. 
The major histocompatibility complex (MHC) class I and II are antigen-presenting 
molecules present on the surface of all nucleated cells and on antigen presenting cells, 
respectively. The human version is called human leukocyte antigen (HLA), and some 
subtypes of genes (alleles) coding for the HLA complex predispose for several – or in 
some instances specific – autoimmune diseases. The strong association between 
HLA-B27 and ankylosing spondylitis is currently the best example of this (37).  There 
is an association between HLA-type and pSS, in particular the HLA-types DR2 and 
DR3 (38). 
Several studies have reported associations between specific single nucleotide 
polymorphisms (SNP) and autoimmune diseases. Some SNPs are related to one 
disease only, while most are found to be associated with several autoimmune diseases. 
SNPs in PTPN22 increase the risk of developing RA, SLE, type 1 diabetes and 
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autoimmune thyroid disease (39), and SNPs in NOD2 leads to an increased risk for 
inflammatory bowel disease and chronic obstructive pulmonary disease (40, 41). 
However, the association between a certain SNP or a combination of SNPs and 
susceptibility to a disease is usually not very strong, most commonly with only a small 
increment in risk (1.1–1.5-fold) (42). Hence, factors additional to genetic variation are 
necessary for disease to develop. Epigenetic modifications that result in altered gene 
expression may be one link between genetic and environmental factors (36).  
1.3.2 Cytokines 
Cytokines are small peptides, produced by cells of the immune system. They act in an 
autocrine, paracrine and/or endocrine fashion, and influence cell growth and 
differentiation; however their main function is signalling between cells. Some 
cytokines are pro-inflammatory and others anti-inflammatory, although this view is a 
simplification. Cytokines are highly pleiotropic, and the effects of a certain cytokine 
are dependent on the local inflammatory environment and the target cells, among 
other factors (43). Most cytokines have a short half-life, act locally, and are found in 
concentrations of ng/mL or lower, challenging conditions that influence the 
measurement and analysis of these peptides. High levels and/or increased production 
of pro-inflammatory cytokines are found in patients with chronic inflammatory 
diseases, such as RA (44), SLE (45) and multiple sclerosis (MS) (46). Amongst 
others, the secretion of the pro-inflammatory cytokines IL-1β, IL-6, TNF-α and 
interferon (IFN)-γ is increased in pSS patients (47, 48).  
1.3.3 The IL-1 system and sickness behaviour 
The interplay of the cytokines controls the direction, amplitude and duration of the 
immune-response. IL-1 is a pro-inflammatory cytokine, released mainly by monocytes 
and macrophages early in the inflammatory cascade. It exists in two biologically 
active forms – IL-1α is found on cell membranes and inside cells, while IL-1β is 
soluble and secreted from the cells. IL-1 has two receptors; IL-1 receptor I (IL-1RI) 
induces signal transduction while IL-1 receptor II (IL-1RII) is a decoy receptor (49). 
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IL-1RAcP is a co-receptor for IL-1RI, necessary for the IL-1 signal to induce pro-
inflammatory gene expression. However, a structurally different variant of this co-
receptor is found on neurons. IL-1RAcPb arrests most, but not all of the IL-1 
signalling, and does not induce pro-inflammatory gene expression. This is proposed to 
be a neuro-protective mechanism; brain inflammation is avoided whereas signals are 
transferred to the CNS (50). Multiple mechanisms to regulate IL-1 activity have 
evolved, and further balance of the IL-1 system is assured by a naturally occurring IL-
1RI antagonist, IL-1Ra, which down-regulates the IL-1 effect by blocking IL-1RI 
(51). Under normal conditions and in healthy subjects, IL-1Ra is found in the range of 
100-300 ng/mL in blood, while IL-1β is in the pg/mL range, and not easily measured 
(52). The concentration of IL-1Ra increases a few hours after an increase in IL-1β. As 
IL-1β is difficult to measure, IL-1Ra can be utilized as a surrogate marker of 
increased activity in the IL-1 system (23).  
IL-1 has been thoroughly investigated in relation to the concept of sickness behaviour 
in animals. Sickness behaviour is a survival-enhancing strategy, observed during 
infection and inflammation (53). It is characterized by sleepiness, social withdrawal 
and loss of appetite, and is a complex and automated behaviour believed to protect the 
sick individual from predators. Several animal studies have explored the pathways 
leading to sickness behaviour, and it seems clear that IL-1 is a fundamental actor in 
this concept (54). In particular, signals leading to sickness behaviour seem to be 
transmitted through the IL-1RI/IL-1RAcPb complex on neurons in the brain. 
Engagement of this receptor complex leads to neuronal signalling, but no 
inflammation (50, 52). This allows behavioural adaptations due to inflammation to be 
initiated through IL-1, without the dangers of inflammation taking place in the CNS 
itself.  
In mice, intraperitoneal or intracerebrovascular injection of IL-1β or the bacterial 
endotoxin lipopolysaccaride (LPS) leads to sickness behaviour within a few hours 
(54, 55). The behavioural effects of IL-1β can be blocked by injections of IL-Ra and 
is not seen in IL-1RI knockout mice (56). IL-1 acts upstream from other pro-
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inflammatory cytokines, such as IL-2 and IL-6 (57, 58). 
Fatigue in humans can be considered a component of sickness behaviour, and human 
experiments have confirmed several of the results from animal studies.  In healthy 
males, intravenous administration of low doses of LPS was followed by increased 
plasma levels of IL-6, TNF-α and IL-1Ra within hours, accompanied by decreased 
mood in a dose-dependent fashion (59). Injection of IL-1 in human leads to chills, 
fever, fatigue, hypotension and nausea (60, 61). Most studies in chronic inflammatory 
conditions report an association between pro-inflammatory cytokines and fatigue, 
although the results are conflicting, see Table 1. This variation may be due to 
differences in patient populations, sample handling and cytokine assessment methods. 
We have previously reported an up-regulation of IL-1Ra in the cerebrospinal fluid 
(CSF) of pSS patients with fatigue, which reflects an intratechal activation of the IL-1 
system (23). 
1.4 Biologic agents 
Biologic agents are immune modulating drugs developed by recombinant DNA 
technology. These drugs offer a targeted strategy in contrast to the nonspecific 
immunosuppressive agents traditionally used to treat most forms of autoimmune- and 
immune-mediated chronic inflammation. However, it is important to keep in mind 
that both classes of drugs merely dampen the disease process, and there is currently 
no definite curative pharmacological treatment for any chronic inflammatory disease. 
There are several classes of biologic agents. These drugs generally inhibit specific 
components or pathways of the immune-system through interference with kinases, 
proteasome or cytokine function, inhibition of T-cell activation, depletion or 
inhibition of B-cells, or inhibition of the homing of immune-cells. 
 
 
 Ta
bl
e 
1 
Se
le
ct
ed
 st
ud
ie
sa
 o
f c
yt
ok
in
es
b  a
nd
 fa
tig
ue
 
D
is
ea
se
 
C
yt
ok
in
e 
Fa
tig
ue
 m
ea
su
re
 
N
o.
 o
f p
ts
.c 
A
ss
oc
. w
ith
 fa
tig
ue
 
PS
S 
(2
2)
 
25
 c
yt
ok
in
es
 
FA
C
IT
-F
, F
SS
, V
A
S 
14
1/
0/
0 
IL
-1
7 
(w
ea
k)
 
PS
S 
(2
3)
 
IL
-1
R
ad
 
V
A
S 
54
/0
/5
3 
IL
-1
R
a 
PS
S 
(2
5)
 
IL
-1
β,
 IL
-2
, I
L-
6,
 IL
-1
0,
 T
N
F-
α 
M
FI
 
60
/0
/1
39
 
N
o 
SL
E 
(6
2)
 
IF
N
-I 
sy
st
em
 
M
FI
-2
0,
 V
A
S 
58
/0
/2
0 
N
o 
SL
E 
(2
6)
 
IL
-2
, I
L-
6,
 IL
-1
0,
 T
N
F-
α,
 IF
N
-α
, T
G
F-
β 
FS
S 
57
/0
/0
 
N
o 
M
S 
(4
6)
 
IL
-1
0,
 T
N
F-
α,
 IF
N
-γ
 
FS
S 
15
/1
5/
0 
TN
F-
α 
an
d 
IF
N
-γ
 
B
C
 (6
3)
 
IL
-6
, I
L-
1R
a,
 sI
L-
6R
, T
N
F-
R
II 
SF
-3
6 
(V
ita
lit
y)
 
50
/5
0/
0 
IL
-1
R
a,
 sI
L-
6R
 
B
C
 (6
4)
 
IL
-1
β,
 IL
-1
R
a,
 sT
N
F-
R
II 
R
A
N
D
, F
SI
 
20
/2
0/
0 
IL
-1
R
a,
 sT
N
F-
R
II 
B
C
 (6
5)
 
IL
-1
R
a,
 sT
N
F-
R
II 
FS
I 
10
3/
0/
0 
sT
N
F-
R
II 
 
B
C
, P
C
 (6
6)
 
IL
-1
β,
 IL
-6
, I
L-
1R
a 
FS
I 
28
+2
0/
0/
0 
IL
-1
R
a 
Tr
C
 (6
7)
 
IL
-6
, T
N
F-
α 
B
FI
-K
 
90
/0
/0
 
N
o 
TC
 (6
8)
 
IL
-6
, I
L-
1R
a,
 sT
N
F-
R
I  
FQ
 
92
/1
91
/0
 
IL
-1
R
a 
 
B
C
, b
re
as
t c
an
ce
r; 
B
FI
-K
, B
rie
f F
at
ig
ue
 In
ve
nt
or
y 
– 
K
or
ea
n;
 F
A
C
IT
-F
, F
un
ct
io
na
l A
ss
es
sm
en
t o
f C
hr
on
ic
 Il
ln
es
s T
he
ra
py
 –
 F
at
ig
ue
; F
SI
, F
at
ig
ue
 S
ym
pt
om
 
In
ve
nt
or
y;
 F
SS
, F
at
ig
ue
 S
ev
er
ity
 S
ca
le
; F
Q
, t
he
 F
at
ig
ue
 Q
ue
st
io
nn
ai
re
; I
L,
 in
te
rle
uk
in
; I
FN
, i
nt
er
fe
ro
n;
 M
FI
, M
ul
tid
im
en
si
on
al
 F
at
ig
ue
 In
ve
nt
or
y;
  M
S,
 
m
ul
tip
le
 sc
le
ro
si
s;
 P
C
, p
ro
st
at
e 
ca
nc
er
; P
SS
, p
rim
ar
y 
Sj
ög
re
n`
s s
yn
dr
om
e;
 R
A
N
D
, R
A
N
D
 3
6-
Ite
m
 H
ea
lth
 S
ur
ve
y;
 S
F-
36
, S
ho
rt 
Fo
rm
 (3
6)
 H
ea
lth
 S
ur
ve
y;
 
SL
E,
 sy
st
em
ic
 lu
pu
s e
ry
th
em
at
os
us
; T
C
, t
es
tic
ul
ar
 c
an
ce
r; 
Tr
C
, t
er
m
in
al
 c
an
ce
r; 
TN
F,
 tu
m
or
 n
ec
ro
si
s f
ac
to
r; 
V
A
S,
 v
is
ua
l a
na
lo
gu
e 
sc
al
e.
   
   
   
   
   
   
   
   
   
   
  
a 
Lo
ng
itu
di
na
l o
r c
ro
ss
-s
ec
tio
na
l s
tu
di
es
; b
 M
ea
su
re
d 
as
 p
la
sm
a 
co
nc
en
tra
tio
n,
 w
ho
le
 b
lo
od
 st
im
ul
at
or
y 
ca
pa
ci
ty
 o
r p
er
ip
he
ra
l b
lo
od
 g
en
e 
ex
pr
es
si
on
; c
 
Pa
tie
nt
s w
ith
/w
ith
ou
t f
at
ig
ue
/h
ea
lth
y 
co
nt
ro
ls
; d
 M
ea
su
re
d 
in
 c
er
eb
ro
sp
in
al
 fl
ui
d.
 
27 
The first biologic agent developed was a TNF-α inhibitor, approved by the US Food 
and Drug Administration for the treatment of RA in 1998 (69). The list of biological 
agents approved for RA has expanded, and now includes several TNF-α inhibitors, 
cytokine inhibitors, and other drugs interfering with the activity of the innate and 
adaptive immune system.  
TNF-α inhibitors have proven to be very effective in several autoimmune diseases, 
such as RA, ankylosing spondylitis and inflammatory bowel disease (70-72). 
However, infliximab, a chimeric monoclonal IgG1 antibody directed against TNF-α, 
was without effect in pSS in a large multicenter placebo-controlled trial (73). Further, 
etanercept, a fusion protein consisting of the soluble human TNF receptor linked to 
the Fc part of human IgG1, showed no effect in pSS on a variety of disease related 
variables (74).    
In contrast, RTX, a chimeric humanized monoclonal anti-CD20 antibody, is reported 
to be efficient in pSS, with improvements in dryness, tender points and fatigue (27, 
28). Patients with shorter pSS disease duration appear to benefit more than patients 
with longer disease duration. RTX seems to have an acceptable safety profile in pSS, 
although several issues still need to be addressed; selection of patients for treatment, 
treatment intervals and duration, and long term outcome of RTX in pSS (75). Despite 
these promising results, no biologic agent has so far been approved for the treatment 
of pSS. 
Currently, three biological drugs are developed to target the IL-1 system; anakinra - a 
recombinant IL-1Ra, canakinumab - an anti-IL-1β monoclonal antibody, and 
rilonacept - a fusion-protein consisting of the extracellular chains of IL-1RI and IL-
1RAcP linked to the Fc portion of IgG.  
1.4.1 Anakinra  
Anakinra (Kineret ™, Biovitrum AB, SE-112 76 Stockholm, Sweden) is a 
recombinant IL-1Ra, currently approved for use in RA, adult Still’s disease and auto-
inflammatory diseases (52). The anti-inflammatory effect is due to inhibition of the 
28 
IL-1 system, through antagonist action at the IL-1RI. It can be self-administered by a 
daily subcutaneous injection in the abdomen or the thigh. Some patients may 
experience a local allergic reaction; otherwise the frequency of side-effects and 
adverse events of the drug is low (76). Anakinra has a half-life of only four to six 
hours, which makes withdrawal easy in case of adverse events. Both endogenous IL-
1Ra and anakinra are capable of crossing the blood brain barrier (BBB), presumably 
through a saturable transport system (51, 77), and has a direct IL-1 inhibiting effect in 
the brain. However, the drug also works through a reduction in the peripheral effects 
of IL-1. Thus, it is still uncertain whether the influence of IL-1Ra on brain signalling 
is due to peripheral or central inhibition of IL-1. 
1.5 Oxidative stress 
Oxidative stress results from an imbalance between the physiological antioxidant 
defences and the production of reactive oxygen species (ROS). ROS are mainly free 
radicals and other highly reactive oxygen species, produced in all cells of an 
organism. The majority of ROS are generated by oxidative phosphorylation in the 
mitochondria and by activated cells of the innate immune system (78). ROS are 
important in bacterial defence and are released through the NADPH-oxidase-
dependent respiratory burst to kill engulfed pathogens. Recent evidence also point to a 
role for mitochondrial ROS in elimination of bacteria in macrophage phagosomes 
through activation of cell surface TLRs 1, 2, and 4 (79). ROS may have a dual role in 
chronic inflammation. It activates the ubiquitous transcription factor NF-κB, 
promoting transcription of a number of pro-inflammatory genes (57), but is also 
reported to dampen the inflammasome activity under certain conditions (52). It has 
been proposed that the redox state of resting inflammatory cells influence the redox 
response to PRR stimulation (80).  
Under normal conditions, pro-oxidant forces are balanced by the anti-oxidant systems. 
Circulating red blood cells contain several anti-oxidant enzymes, such as superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), and are highly 
potent scavengers of ROS. Anti-oxidants and reducing enzymes are present in plasma 
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and ubiquitously distributed in most cells. However, infection or autoimmune disease 
accompanied by chronic inflammation may lead to increased production of ROS in 
activated phagocytes, outplaying the anti-oxidant defences (79). This disruption of the 
redox balance results in a state of increased oxidative stress, as reported in SLE (81), 
RA (82), and MS (83).  
ROS are difficult to measure due to short half-life and local variations in 
concentration from one tissue or even one cell to another. End products of oxidative 
stress are more stable and can be examined in serum, blood cells, urine, cerebrospinal 
fluid and tissue samples. Therefore, most oxidative stress assays have been developed 
based on lipid-, protein- and DNA oxidation products.  
Oxidative attack on macromolecules is a relatively unspecific process, but some ROS 
are known to cause damage to certain amino acids or lipids, resulting in more specific 
products. One example is the hypochlorous acid (HOCl) generated in activated 
neutrophils by myeloperoxidase, contributing to the formation of advanced oxidation 
protein products (AOPP). AOPP comprise pentosidine, proteins cross-linked by 
dityrosine and protein carbonyls (PC), in addition to other chromophores, all of which 
show absorbance at wavelength 340 nm (84). Protein oxidation probably reflects the 
general level of oxidative stress in an individual, although lipid peroxidation is the 
most widely used marker of oxidative stress.  
1.5.1 Oxidative stress in pSS and fatigue 
It is not unlikely that oxidative stress is involved in the pathogenesis of pSS. 
Oxidative stress may contribute to salivary tissue destruction (85), and increased 
levels of oxidative stress markers in salivary ductal cells from sSS patients have been 
reported (86). Moreover, pro-oxidant enzyme expression is increased in the 
conjunctival epithelium in sSS (87), and oxidative stress has been proposed as a 
treatment target in SLE (88). Further, oxidative stress may play a role in fatigue 
generation. Several studies point to an association between oxidative stress and 
fatigue in CFS (89), SLE (90) and fibromyalgia (91), Table 2. Despite the above 
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mentioned investigations of oxidative stress in SS (85-87), plasma levels of oxidised 
proteins have not been reported, and the relationship between oxidative stress and 
fatigue has never been explored in pSS. 
 
Table 2 Selected studies of oxidative stress and fatigue. 
Condition Measure of OS No.a  Assoc. fatigue Comments 
CFS (92) F2-isoP 25/23       Yes Fatigue not assessedb, pediatric CFS 
CFS (93) MDA 40/40       No Fatigue not assessedb 
CFS (89) F2-isoP 47/34       Yes High CV risk patients excluded 
CFS (94) PC 36/16       Yes Fatigue not assessedb 
CFS (95) MDAc 31/41       Yes Fatigue not assessedb 
FMS (91) F2-isoP 48/96       Yesc  
SLE (90) F2-isoP 95/103       Yesc   
CFS, chronic fatigue syndrome; CV, cardiovascular; FMS, fibromyalgia syndrome; F2-isoP, F2-
isoprostane (urine); MDA, malondialdehyde (serum); OS, oxidative stress; PC, protein carbonyl 
(serum); SLE, systemic lupus erythematosus.                                                                                          
a Patients/healthy controls; b Investigated association with CFS/ME, no fatigue scale reported; c No 
significant difference in oxidative stress between patients and healthy controls, more oxidative stress 
in patients with more fatigue. 
 
1.6 Genetics 
Most diseases have a heritable component. This pattern was proposed even before the 
gardener Gregor Mendel published his famous paper on inheritance of certain traits in 
the pea plant in 1866 (96). The deoxyribonucleic acid (DNA) was first isolated by 
Swiss physician Friedrich Miescher in 1869, and the double helix structure of the 
DNA was described by James D Watson and Francis Crick in Nature in 1953 (97), a 
discovery rewarded with the Nobel Prize in Physiology or Medicine in 1962. The 
euchromatic human genome was mapped in 2003, a process that took 13 years and 
cost 3 billion USD (98). The abilities of the gene sequencing technologies have since 
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expanded exponentially, and at present time the human genome can be mapped in 
hours, at a cost of less than 10 000 USD (99).  
1.6.1 DNA and genes  
DNA consists of two long strings of nucleotides, linked to backbones made of 
alternating sugar (deoxyribose) and phosphate. The nucleotides are adenine (A), 
guanine (G), thymine (T) and cytosine (C), and these four nucleotides form hydrogen 
linked base-pairs between the strands; A-G and C-T. The haploid human genome 
consists of more than 3 billion base-pairs. The two DNA strands run in opposite 
directions and are wrapped around each other in the structure of a double helix. DNA 
is tightly packed in structural units named nucleosomes, consisting of a histone 
octamer with 147 base-pairs wrapped around it. The nucleosomes are packed closely 
together, and this structure enables large genomes to be contained in the nucleus of a 
single cell, Figure 1.     
 
Figure 1. DNA is tightly packed into chromosomes, contained in the nucleus of the cell.  
 
A gene is the molecular unit of heredity. It is a defined sequence of DNA that encodes 
a functional unit, either a protein or a RNA molecule. The sum of the genes and the 
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non-coding DNA sequences in an organism or cell is known as a genome. The human 
genome is stored on 46 chromosomes, 22 pairs of autosomes and one pair of sex 
chromosomes. A locus is the region of a chromosome in which a particular gene is 
stored (100). The human genome contains approximately 30 000 (25 000) genes, and 
the genetic code is about 99.8% similar across the human population (101). 
1.6.2 Single nucleotide polymorphisms 
The 0.2% variation in genetic code across mankind is mainly the result of copy 
number variation (CNV) and SNPs (101). A SNP is a variation in the DNA sequence 
at a specific position, due to a difference in a single nucleotide –A, T, C or G – 
between members of the same species, or between the paired chromosomes in one 
individual. The more common variant is denominated the major allele and the rare 
variant the minor allele. By definition SNPs occur with a minor allele frequency 
(MAF) of >0.5% in the population under study, otherwise the polymorphism is 
considered a rare or private variant (101). SNPs may fall within coding (exon) or non-
coding (intron) regions of genes, or in the intergenic regions. Also, the consequences 
of a SNP depends on its position (locus) and nucleotide sequence; a synonymous 
polymorphism leaves the gene product unaltered, a mis-sense polymorphism results in 
a different amino acid, and a non-sense polymorphism results in a premature stop 
codon (100). Variations in the DNA sequence may influence a person’s susceptibility 
to disease, sometimes through changes in the immunological response to pathogens, 
drugs, chemicals and vaccines. Genome-wide association studies (GWAS), testing 
hundreds or thousands of samples for disease associations with several hundred 
thousand SNPs, have successfully uncovered many genetic variants that increase the 
risk of complex diseases.  
It was assumed that mapping the human genome would reveal the patterns of 
heritability in complex diseases, however, disease-associated SNPs, alone or in 
combination, usually account for only a small proportion of the inheritable component 
of disease risk (42, 102), with an overall risk of 1.1-1.5 in most cases. Genetic 
variation has been extensively studied in autoimmune diseases, and even when several 
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disease-associated SNPs are found in one individual, the clinical pattern is not fully 
explained.   
1.6.3 Epigenetics 
Epigenetics is the study of heritable and potentially reversible changes in genome 
function not involving alterations in the DNA nucleotide sequence. Epigenetic 
modifications can occur in response to environmental factors and play a fundamental 
role in the regulation of gene expression. The epigenome, i.e. the epigenetic state of 
an organism, is proposed to be just as important as the genome to normal 
development (103). In contrast to genetic changes, epigenetic alterations arise in a 
gradual manner, leading to a progressive change in expression of specific genes. The 
major epigenetic mechanisms, histone modifications and DNA methylation, lead to 
conformational changes in the chromatin structure. Hypermethylation of tDNA makes 
chromatin more condensed, a process that impairs binding of transcription factors and 
ultimately leads to decreased gene expression from these loci (104). This is important 
for imprinting, the final differentiation of cells, as DNA methylation patterns ensure 
that fully differentiated cells do not enter aberrant gene expression. Demethylation of 
the DNA is reported to be involved in both cancer and autoimmune disease 
development (105, 106). Hypomethylation of the TNFSF7 promoter region in CD4+ 
T-cells, associated with increased expression of the T-cell surface molecule CD70, 
has been reported in pSS (107). CD70 is a B-cell co-stimulatory molecule that 
promotes plasma cell differentiation and immunoglobulin production; thus aberrant 
expression of CD70 may lead to B cell auto- and hyperactivity. Epigenetic 
modifications are reversible, and could represent new treatment targets in 
autoimmune diseases.    
1.6.4 PSS, fatigue, and genetics 
Genetic variation has mainly been investigated in relation to fatigue in CFS (108, 
109) and in cancer related fatigue (110, 111). A recent systematic review covering 
SNP analyses, gene expression studies and bioinformatics data-mining studies in 
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relation to fatigue identified 33 articles on CFS and 8 articles regarding conditions 
other than CFS. The main conclusion was that “….there is great heterogeneity within 
genetic studies of fatigue in terms of sample sizes, sample descriptions and findings” 
(111). Genes related to the hypothalamus-pituitary-adrenal (HPA)-axis and to the 
immune system were implicated in more than one study, but otherwise the complexity 
of the findings was more striking than the unity. So far no single gene variant that 
clearly increases the susceptibility to fatigue has been found. Genetic variation has 
never been explored in relation to fatigue in pSS, but it is not unlikely that certain 
gene variants or SNPs may be of importance. It is a conundrum why some pSS 
patients develop more fatigue than others, independent of disease activity or co-
morbidity. Maybe parts of the explanation can be found in the genetic or epigenetic 
makeup of each individual.    
It is an interesting thought that epigenetic modifications influence fatigue, and the 
epigenome could represent a connection between environmental factors and fatigue. 
This hypothesis is new and so far virtually no research has been performed in this area 
(112). 
 
2. Aims of the study 
x Write a review article of the current knowledge of biological 
mechanisms of chronic fatigue in inflammatory and non-inflammatory 
conditions. 
x Investigate the efficacy and safety of IL-1 inhibition on fatigue in pSS.   
x Evaluate the level of plasma oxidative stress markers in pSS as 
compared to healthy individuals, and further explore any associations of 
oxidative stress with fatigue in pSS. 
x Investigate SNPs in selected genes in relation to fatigue in pSS.  
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3. Overview over Papers I-IV 
FSS, VAS
4 weeks
No effect on fatigue in primary outcome. 
Paper I: Interleukin-1 inhibition and fatigue Post hoc analysis indicate reduction in 
in primary Sjøgren`s syndrome fatigue from anakinra.
Paper II: Oxidative stress, as measured Increased protein oxidation in pSS. 
by protein oxidation is increased in Not associated with high fatigue.
primary Sjøgren`s syndrome
72 pSS patients
SUS                
Paper III: A possible genetic association A trend for association between SNP in
with chronic fatigue in primary Sjøgren`s SLC25A40 and pSS high fatigue vs controls,
syndrome: a candidate gene study and PKN1  and pSS high vs low fatigue.
Review article. Part I Part II
Paper IV: Biological mechanisms 
of fatigue
26 pSS patients 
(SUS)
15 healthy 
controls
Fatigue VAS
FSS
AOPP
PC
AOPP and PC in pSS 
compared to HC. pSS split 
into high (FSS>6) and low 
fatigue.
26 pSS patients 
(SUS)
13 patients 
anakinra
13 patients 
placebo
Primary outcome - reduction 
in fatigue? 
Efficacy and safety of 
anakinra in pSS
Review article. 
What is fatigue?
How to measure fatigue. 
Fatigue and non-inflammatory 
conditions.
Fatigue in chronic inflammatory 
conditions.
Confounding factors.
The biological origin of fatigue. 
Cytokines and sickness 
behaviour.
HPA-axis.
Oxidative stress and 
mitochondrial dysfunction.
Genes and fatigue
207 p S 
patients (SUS + 
HUS)
376 healthy 
controls (Norway 
+ Sweden)
Fatigue VAS 
FSS
Genotyping, 85 
SNPs, 12 genes
193 patients and 70 SNPs in 
11 genes passed quality 
control. pSS split into high 
(VAS>50) and low fatigue
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4. Subjects and methods 
4.1 Patients with pSS 
The patient register used to recruit the pSS patients included in this dissertation was 
set up by our research group, and the work was led by professor Roald Omdal (113). 
The register is based on a thorough review of the medical charts of all patients with a 
pSS diagnosis referred to SUS in 1980 – 2005. Patients who fulfilled the AECG 
criteria (10) were included, and patients close to fulfilling the criteria were invited to 
a new screening visit. In addition, the results of all MSG biopsies performed at SUS 
during the same time period were identified, and medical charts of patients with a 
focus score ≥ 1 were reviewed. Ninety-nine patients were identified in 2005. The 
register was updated in 2008, including 125 pSS patients aged 18-80 years living in 
Rogaland County, Norway. This updated register was used to recruit patients to the 
clinical trial and the oxidative stress assessment (Paper I and II).  
For the genetic analysis, patients from both the 2005 SUS cohort and the 2005 HUS 
cohort were included. The HUS cohort was identified by investigators at the 
Department of Rheumatology, HUS, through assessment of medical records of all 
patients fulfilling the ICD-10 code for pSS (M35.0) from 1999 to 2005. A total of 141 
patients fulfilling the AECG criteria were identified. Seventy-two patients from SUS 
and 135 patients from HUS were included in the genetics study (Paper III).  
All patients and healthy controls who participated in any of the studies or assessments 
gave written informed consent to participate, and all investigations were carried out in 
compliance with the principles expressed in the Declaration of Helsinki. The clinical 
trial was registered at ClinicalTrials.gov (number NCT00683345) and was approved 
by the regional ethics committee, REK-Nord, Norway.   
4.2 Healthy controls 
Healthy controls (HCs) were included for Paper II and Paper III. Apart from age and 
gender, no demographic or clinical information was registered in the healthy subjects. 
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None of the HCs had known neurological, immunological or active malignant disease, 
and the HCs were not related to the pSS patients.  Fifteen HCs, recruited among 
employees at SUS, were included in Paper II to provide reference values for oxidative 
stress measures. Three hundred and seventy six HCs, both Norwegian and Swedish, 
were included in Paper III to give a comparison to the local genetic background. The 
Swedish HCs (n=236) were partly population based and partly recruited from blood 
donors. The Norwegian HCs (n=140) were recruited from hospital staff, friends and 
colleagues of the patients. 
4.3 Blood and urinary samples 
All pSS patients were screened at inclusion in 2005 or 2008 and once again for the 
clinical trial. The screening included routine haematological and biochemical tests in 
addition to autoantibody, complement and immunoglobulin assessment. Conventional 
urinary analyses with dip-stick and protein/creatinine ratio were performed. The same 
combination of analyses was repeated at week 0, week 2, week 4 and week 5 for the 
patients included in the clinical trial.   
4.4 Evaluation of depression 
The Beck Depression Inventory (BDI) was used to assess mood (114). BDI is a 
generic instrument that evaluates the current level of depression, widely used in 
clinical studies. A BDI score below 13 indicates no depression, while a score of 14-19 
is regarded to represent mild depression. A cut-off score of ≥ 20 was used in Paper I 
and II to exclude moderately to seriously depressed individuals.  Mood was assessed 
in all patients in 2005 and 2008, and the assessment was repeated for the patients 
included in the clinical trial. 
4.5 Evaluation of fatigue 
The Fatigue Severity Scale 
The FSS is a generic fatigue measuring instrument (15). The FSS score is the mean of 
the sum of scores in 9 items, each rated from 1-7. Patients are asked to relate the 
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questions to the last two weeks. A FSS score of 3 is commonly applied as a cut-off 
value for fatigue in systemic lupus erythematosus (SLE) and was used in this 
dissertation. The FSS was selected because it is unidimensional, has a high sensitivity, 
reliability and internal consistency, and is validated and used in pSS and a number of 
other diseases (15, 115, 116) 
The fatigue visual analogue scale 
A horizontal 100 mm line with vertical anchoring lines represents the fatigue VAS 
used. The wording at the left end (0 mm) is “No fatigue” and at the right end (100 
mm) is “Fatigue as bad as it can be”. The patients are asked to rate their fatigue at 
present.  The VAS is a single uni-dimensional measure, relatively easy for patients to 
understand and score, and sensitive to change (117, 118).  
4.6 Paper I  
Inclusion criteria were: pSS according to the AECG criteria (10), Caucasian descent 
and Norwegian language. Exclusion criteria were: moderate to severe depression 
(BDI score ≥ 20 (114)), untreated comorbidity that may explain the presence of 
fatigue (i.e. heart failure, untreated hypothyroidism), lack of fatigue (FSS ≤ 3) (15), 
neutropenia (neutrophil count < 1.5 x 109/L), anemia (haemoglobin < 100g/L), 
present or recurrent infections, pregnancy, lactation, or concurrent treatment with 
biologic agents. 
Twenty-six patients were deemed to be ineligible based on a review of their medical 
record. Thus, 99 patients were sent an invitation to participate in the study, which for 
logistic reasons was conducted in two phases. Fifteen patients agreed to participate in 
the pilot trial in 2008, of whom eight were included. The remaining 84 patients were 
invited to participate in the main study in 2010, and 18 patients were included. Figure 
2 illustrates the inclusion and reasons for non-inclusion. 
The study was designed as a single centre, prospective, randomised, double-blind 
placebo-controlled parallel-group trial. Anakinra or placebo was given as a daily 
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subcutaneous injection for four weeks.  All patients had a total of five study visits; 
baseline (inclusion), week 0 (first injection), week 2, week 4 (last injection) and week 
5. Blood samples were drawn and fatigue and safety was assessed at every visit, 
whereas depression was assessed at baseline and week 5. All study visits took place at 
SUS. 
125 pSS patients in 
the 2008 database, 
medical chart review
99 patients invited to 
2008 study
84 patients invited to 
2010 study
26 patients agreed to 
participate
18 patients included in 
2010 study
26 patients not eligible:
-16 comorbid disease
-2 treated with biologics
-3 not Norwegian
-2 depressed
-2 moved out of district
-1 not willing                     
58 patients did not want 
to participate
-Time consuming 
protocol
-Unvillingness of daily 
injections
8 excluded:
-2 depressed
-3 FSS < 3
-2 changed their mind
- 1 pregnant
15 patients agreed 
to participate
8 patients included 
in 2008 study
7 excluded:
-3 depressed
-4 FSS < 3
 
Figure 2. Flowchart of inclusion in the study. The pilot study was conducted in 2008 and the 
main study in 2010. All patients underwent the same procedures.                                                            
FSS, Fatigue Severity Scale; pSS, primary Sjøgren`s syndrome. 
 
Study drug and randomisation 
The 26 participants were randomly assigned to receive double-blinded therapy with 
either anakinra (KineretTM, BioVitrum AB, SE-112 76 Stockholm, Sweden) 100 
mg/day or placebo (0.9% NaCl in an identical syringe). The treatment allocation took 
place after complete inclusion using a computer generated randomisation list 
administered by the hospital pharmacy. We used simple randomisation, with a 1:1 
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allocation, and neither the investigators, study nurses nor the patients were aware of 
the assigned treatment.  
The study was conducted in two phases, as placebo could not be produced in syringes 
identical to the active drug in 2008. The eight patients included in the 2008 pilot trial 
received their daily injections at the hospital. The active drug or placebo was prepared 
in identical syringes by a research nurse who was unblinded and not involved in 
patient handling. Placebo could be produced in syringes identical to the active drug in 
2010, with a durability that allowed the patients to receive a 14 days supply of the 
allocated treatment at week 0 and week 2. A study nurse supervised the first injection 
at week 0, and trained the patients to self-administer the drug or placebo. The patients 
registered each injection in a form, and the form and the empty syringes were 
collected at the visits at week 2 and week 4.  
Outcome measures  
The primary outcome measure was a group-wise comparison of fatigue scores at week 
4, adjusted for baseline values. Secondary outcome measures were the change in 
fatigue score within each treatment-group, and safety issues. As a post-hoc outcome 
the proportion of patients who achieved a 50% reduction in fatigue in each treatment-
group was compared.   
4.7 Paper II 
Plasma samples from the 26 patients included in the clinical trial (described in detail 
for Paper I) were used for Paper II, in addition to samples from 15 healthy control 
subjects, who voluntarily donated blood to the study. The healthy control group 
comprised 12 females and 3 males, with a median age of 49 [27-65] years. No other 
clinical information was registered, as the purpose of the control group was to provide 
reference values for oxidative stress measures, not to serve as case controls for the 
patients. Blood samples were drawn from patients at week 0, before any interventions 
or examinations had taken place. EDTA blood was centrifuged for 15 minutes at 2000 
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G at 4oC and stored in aliquots at minus 72oC until analysed. Freshly thawed samples 
were used for both AOPP and PC measurements. 
AOPP 
AOPP was assessed by a method recently developed by our group (119). Briefly, 40 
μl of plasma was transferred to a 96 well microplate, and citric acid (60 μl; 0.20 
mol/L) was added. The absorbance at 340 nm was read after 2 minutes on a 
microplate shaker. The external calibration standards used were chloramine-T diluted 
in citric acid with potassium iodide added, and the concentrations of AOPP are 
expressed as μmol/l chloramine-T equivalents. 
PC 
We used a modified version of a previously described method to analyse PC (120). 
Briefly, 2,4-dinitrophenylhydrazine was used to derivatize the carbonyl groups to 
form stable hydrazones, and excess reagent was separated by reversed phase high 
performance liquid chromatography (RP-HPLC, Waters Alliance e2695 connected to 
a Waters 2487 Dual Absorbance Detector). The 20 μl sample was then injected onto a 
Gemini C18 security guard column (5μm, 2 mm x 4 mm, Phenomenex, USA). The 
HPLC mobile phase consisted of (A) 0.1% trifluoroacetic acid and (B) 100% 2-
propanol, with an elution profile as follows: 0–2 min, 10–90% B linear gradient; 2–3 
min, isocratic 90% B, 3–6 min, isocratic 10% B. The flow rate was held at 0.6 
ml/min. Eluted hydrazones and total protein were measured simultaneously at 
absorption wavelengths of 366 nm and 280 nm, respectively, and PC concentrations 
were reported as nmol/mg protein. 
4.8 Paper III 
A total of 207 patients were included for the candidate gene study, 72 from the SUS 
cohort and 135 from the HUS cohort. Matched control samples were collected from 
Sweden (n=236) and from Norway (n=140). DNA was extracted from the blood 
samples according to standard procedures. We choose a panel of SNPs in 12 genes; 
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the gene selection was based on previous studies of gene expression in CFS (108, 
121, 122). The genes were APOA2, EIF2B4, EIF4G1, SLC25A40, SLC25A16, CRAT, 
MRPL23, COX8A, ABCD4, COX11, PKN1 and PEX16. The GoldenGate Assay 
(Illumina Inc, San Diego, CA, USA) was used to genotype 85 SNPs in the 12 genes. 
Samples with a call rate <0.90, SNPs with Hardy-Weinberg equilibrium test p-values 
< 0.001 and SNPs with a minor allele frequency (MAF) < 0.01 or more than two 
alleles were excluded from further analysis. The MAF in the control samples from 
Norway and Sweden were found to be similar and the control subjects were therefore 
merged to one cohort. After quality control, 193 patients and 70 SNPs in 11 genes 
were available for analysis. The patients were dichotomised according to fatigue 
scores, with a VAS score < 50 (N=53) classified as “low fatigue” and a VAS score ≥ 
50 as “high fatigue” (N=140).  
4. 9 Paper IV - Review article 
This is a non-systematic review article. The literature search was performed based on 
the authors’ preferences, and included articles were regarded by the authors to be of 
high quality, relevant and/or describing interesting hypotheses. A special emphasis 
was put on the description of sickness behaviour and fatigue. 
4.10 Statistical methods 
Results are reported as mean ± standard deviation (SD) when normally distributed, 
otherwise as median and range.  The Fisher’s exact test and the Students t-test were 
used for the comparison of categorical and continuous data, respectively. In Paper I, 
Analysis of covariance (ANCOVA) was used to evaluate changes from baseline to 
week 4 between groups, and Friedman’s test for repeated measures was used to 
analyse changes over time within groups. T-tests were used in Paper II to compare the 
levels of AOPP and PC between the patients and HC, and between patients with high 
and low fatigue after the group was dichotomised based on FSS scores. Further, we 
used “limits of agreement” to test the agreement between AOPP and PC after z-scores 
were calculated.  In Paper III, logistic regression analysis was used to explore the 
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relationship between SNP genotype and high/low fatigue scores. A p-value of < 0.05 
was considered significant in Paper I and II, and a p-value of ≤ 0.04 was considered 
significant in Paper III due to multiple comparisons. Analyses were performed using 
SPSS version 15.0 (Paper I, II, III) and SNP & Variation Suite 7 (Golden Helix, 
Bozeman, MT, USA) (Paper III). The Genetic Power Calculator was used for the 
genetic analysis (Paper III) (123). 
 
5. Summary of results 
Paper I 
This double-blind, placebo-controlled parallel group study included 26 pSS patients, 
who were randomised to receive either the IL-1Ra anakinra or placebo. The two 
groups of patients were comparable in demographic and biochemical variables, and 
patients with moderate to serious depression were excluded. The study lasted 4 
weeks, and the active drug (anakinra 100mg/day) or placebo (0.9% NaCl in identical 
syringe) was self administered by the patients. Study-visits were scheduled at week 0 
(start of study), week 2, week 4 (end of study) and week 5 (safety follow-up). Fatigue 
was assessed by fatigue VAS and FSS at all study visits. One patient did not show at 
week 4, and was excluded from the analysis. The primary outcome, a baseline-
adjusted reduction in fatigue at week 4 in the active drug group as compared to the 
placebo group, was not achieved (p=0.19). However, as a post-hoc outcome, the 
proportion of patients in each group who reached a 50% reduction in fatigue was 
calculated. Six out of 12 patients on active drug and 1 out of 13 patients on placebo 
reached this outcome (p=0.03).  
Conclusion: This study did not achieve its primary outcome, a significant reduction in 
fatigue after treatment with an IL-1Ra. However, post hoc analysis indicates that IL-1 
blockade has a strong effect on fatigue, and new studies of IL-1Ra and fatigue are 
warranted. 
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Paper II 
In this paper we compared the serum level of oxidised proteins in pSS and in HC. 
Blood samples were drawn from 26 pSS patients (median age 55, range 18-80 years) 
and 15 HC (median age 49, range 27-65 years). Protein oxidation was measured using 
AOPP and PC. Fatigue was assessed in the pSS patients using fatigue VAS and FSS. 
Significantly increased levels of oxidative stress were detected in the pSS patients 
compared to the HC. This accounted for both AOPP (p<0.002) and PC (p=0.0005). 
There was no association between fatigue and protein oxidation in pSS. None of the 
demographic (age, gender, smoking), clinical (disease duration, cardiovascular 
disease, BMI, depression) or biochemical (neutrophil cell count, C-reactive protein, 
creatinine, complement factor C4, presence of anti-SSA/SSB antibodies) variables 
were associated with protein oxidation as measured by AOPP or PC. 
Conclusion: Oxidative stress, as measured by protein oxidation, is significantly 
increased in pSS, but is not associated with fatigue.   
 
Paper III 
A total of 207 patients from HUS (N=135) and SUS (N=72) and 376 HCs were 
included in this paper. Fatigue was assessed with VAS and FSS. Genotyping of 85 
SNPs in 12 selected genes was performed; the genes were selected based on previous 
gene expression studies in CFS. 193 patients and 70 SNPs in 11 genes were available 
for analysis after quality control. The fatigue scores were dichotomized, with a VAS 
score ≥ 50 representing “high fatigue” (N=140) and a score < 50 representing “low 
fatigue” (N=53). Logistic regression was used to explore allelic associations with 
pSS/high/low fatigue. In the pSS case versus control analysis, signals of association 
with pSS were detected for one SNP in SLC25A40 (unadjusted p=0.007) and two 
SNPs in PKN1 (both p=0.03), Table 3. The association with SLC25A40 was stronger 
in the analysis of only pSS high fatigue patients versus controls (p=0.002). In the 
case-only analysis of pSS high fatigue versus pSS low fatigue, one SNP in PKN1 
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displayed an association (p=0.005). When all analyses were corrected for the number 
of genes and traits (pSS, pSS with high fatigue, pSS with low fatigue) tested, only the 
association between rs10276819 in SLC25A40 in the pSS high fatigue versus healthy 
control analysis remained borderline significant (p=0.066). Power to detect association 
was 5-42%. 
Conclusion: We detected a trend for association between genetic variation in the 
genes SLC25A40 and PKN1 and fatigue. The association with SLC25A40 remained 
borderline significant after correcting for multiple testing, and replication studies are 
warranted.  
 
Paper IV 
This paper is a non-systematic review article of the biological mechanisms of fatigue. 
Fatigue is defined as an overwhelming sense of tiredness, lack of energy and feeling 
of exhaustion (15), and the challenges associated with the assessment of fatigue are 
described. Fatigue is a subjective experience, and self-reported instruments are 
necessary for fatigue evaluation. Fatigue is common in both non-inflammatory and 
inflammatory conditions, with Parkinson’s disease and cancer related fatigue as 
examples of the former, and SLE and pSS examples of the latter. The article describes 
factors confounding to fatigue, with a special emphasis on depression. The biological 
origin of fatigue is the main part of the article, with a thorough description of the IL-1 
system and sickness behaviour. Other biological mechanisms for fatigue are also 
important, in particular oxidative stress, genetic variation and alterations in the 
function of the HPA axis.  
Conclusion: There are biological and psychological mechanisms for fatigue. In a 
clinical perspective it is important to distinguish these mechanisms, as it may 
influence the choice of treatment for the individual patient. 
.   
46 
 
Table 3. Allelic association of individual SNP by logistic regression 
    pSS cases vs controls    MAF   
Allele Gene OR (95% CI) P pSS (n=193) Controls (n=376) 
rs10276819 SLC25A40 0.5 (0.2 to 0.8) 0.007 0.033 0.072 
rs3786654 PKN1 1.3 (1.0 to 1.7) 0.03 0.39 0.32 
rs10416904 PKN1 1.6 (1.1 to 2.5) 0.03 0.1 0.07 
rs2241362 PKN1 0.9 (0.7 to 1.3) 0.63 0.2 0.21 
  PSS+ vs controls MAF   
Allele Gene OR (95% CI) p  pSS+ (n=140) Controls (n=376) 
rs10276819 SLC25A40 0.3 (0.1 to 0.7)  0.002 0.025 0.072 
rs3786654 PKN1 1.4 (1.0 to 1.8) 0.03 0.39 0.32 
rs10416904 PKN1 1.5 (0.9 to 2.4) 0.11 0.1 0.07 
rs2241362 PKN1 0.7 (0.5 to 1.0) 0.08 0.16 0.21 
  PSS+ vs pSS-   MAF   
Allele Gene OR (95% CI) p  pSS+ (n=140) pSS- (n=53) 
rs10276819 SLC25A40 0.4 (0.1 to 1.3) 0.14 0.025 0.06 
rs3786654 PKN1 1.1 (0.7 to 1.8) 0.65 0.39 0.37 
rs10416904 PKN1 0.8 (0.4 to 1.5) 0.46 0.1 0.12 
rs2241362 PKN1 0.5 (0.3 to 0.8) 0.005 0.16 0.3 
The table shows p-values from a logistic regression on allelic frequencies, three outcomes were 
tested: cases with pSS versus controls, pSS cases with high fatigue versus controls, pSS cases with 
high fatigue versus pSS cases with low fatigue.                                                                                  
CI, confidence interval; MAF, minor allele frequency; PSS+, primary Sjögren`s syndrome with high 
fatigue; PSS-, primary Sjögren`s syndrome with low fatigue. 
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6. Discussion 
The research reported in this dissertation is based upon the hypothesis that there are 
biological mechanisms for fatigue in pSS. We have tested this hypothesis in several 
novel ways; through exploration of cytokines, genes and oxidative stress. We report 
the first clinical trial of IL-1 inhibition in pSS, and the results clearly point to a 
positive effect of the intervention. Further, our study is the first to show that plasma 
levels of oxidised proteins are significantly increased in pSS, although not associated 
with fatigue. Finally, we have investigated genetic variation in relation to fatigue. 
There were no significant signals of association between fatigue and SNPs in the 12 
candidate genes selected for our study.   
6.1 Evaluation of the main findings 
Our clinical trial of IL-1 blockade shows that anakinra is safe for short-term use in 
pSS. Post hoc analysis of the results indicates a clear improvement in fatigue in the 
patients who received the active drug compared to patients on placebo. This clinical 
trial was initiated as a hypothesis-testing study, based on the concept of sickness 
behaviour. Sickness behaviour occurs in animals after administration of LPS or pro-
inflammatory cytokines, and IL-1 is a key actor. Fatigue can be considered a human 
parallel to sickness behaviour, and our study offers support to this concept. Several 
other recent studies have also utilised biological drugs in the treatment of fatigue. 
RTX has shown promise in pSS (27, 28), and in secondary endpoints in CFS (21). 
Further, IL-6 blockade is reported to reduce fatigue in SLE (30) and RA (124), and 
TNF-α inhibitors reduce fatigue in RA (31). Taken together, these studies indicate 
that specific components of the activated immune system are important in fatigue 
signalling, and that inhibition of these factors reduces fatigue.      
The study was not able to meet the primary endpoint, a baseline-adjusted 
improvement in fatigue VAS at week 4. It is not unlikely that low power due to too 
few patients is the main reason this endpoint was not achieved. All pSS patients in 
southern Rogaland were invited, but after baseline screening only 26 patients were 
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eligible and willing to participate. One way to include more patients would be to 
collaborate with other regional or national centres, and we suggest this option is 
considered for future treatment studies in pSS.  
Oxidative stress, assessed by plasma protein oxidation, is increased in pSS compared 
to healthy individuals. This is not unexpected, as inflammation and oxidative stress 
are intimately connected. However, earlier studies have indicated that oxidative stress 
and mitochondrial dysfunction may contribute to fatigue in CFS (89, 94), SLE (90) 
and fibromyalgia (91), Table 2. The results of our study are conflicting. One possible 
explanation is that most studies of oxidative stress and fatigue have measured lipid 
peroxidation; only one study has investigated and found an association between PC 
and fatigue (94). However, oxidative stress is assumed to be a general process, and it 
is unlikely that extensive lipid peroxidation would not be accompanied by protein 
oxidation. A more likely reason for the conflicting results is that protein oxidation is 
not important for fatigue generation in pSS.  
Genetic variation is known to influence most human traits and conditions. It seems 
intuitively appealing that genetic polymorphisms could contribute to fatigue 
susceptibility or protect from fatigue. We investigated SNPs in 12 candidate genes, 
and detected signals of association for three SNPs in PKN1and one SNP in 
SLC25A40, Table 3. The SNP rs10276819 in SLC25A40 was associated with pSS, 
and this association was even stronger when only the pSS patients with high fatigue 
were analysed versus the controls (p=0.002, OR 0.3 (CI 0.1-0.7). MAF for this SNP 
was 0.025 in pSS with high fatigue, 0.06 in pSS with low fatigue and 0.072 in 
controls, Table 3. This illustrates the possible protective effect of the minor allele. 
The SNP rs2241362 in PKN1 was associated to high fatigue in the case-only analysis 
of pSS high fatigue versus pSS low fatigue. Due to the 11 genes and three traits under 
investigation, a p-value cut off < 0.0015 (0.05/33) was necessary for statistical 
significance. When adjusting for multiple analysis, the SNP in SLC25A40 remained 
borderline significant, while the association signals from PKN1 were non-significant. 
Thus, we cannot conclude that there is an association, and replication studies are 
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warranted. SLC25A40 encodes a mitochondrial protein, widely expressed in the brain 
but also in the periphery (125). PKN1 is ubiquitously expressed, and the encoded 
protein is involved in apoptosis, cell-signalling and negative regulation of NF-κB 
(126). Polymorphisms in these two genes may influence biological pathways 
connected to inflammation and oxidative stress, ultimately related to fatigue 
generation. Obviously, our results only relate to the genes examined, and it is likely 
that other genes also influence the susceptibility to fatigue. An inherent challenge 
with genetic studies is patient recruitment, as several thousand individuals may be 
needed to detect genome-wide significance in GWAS. The need of a large sample 
size is due to the large number of significance tests performed simultaneously – one 
for each SNP or gene. A candidate gene approach reduces the number of tests 
performed, and thereby reduces the necessary sample size. We recruited pSS patients 
from two hospitals covering 18% of the Norwegian population, but still achieved a 
relatively low power of 5-42%. With a higher power we might have been able to 
detect other associations, and the reported associations might have been stronger. We 
cannot exclude a type II error due to low power. There is a dearth of genetic studies 
on fatigue in well-characterised patients, but with more research we believe several 
significant associations will be found. Future studies should focus on including even 
larger sample cohorts, probably through national and international collaboration. A 
GWAS focusing on fatigue in pSS would be of great interest.   
6.2 Evaluation of methods 
Fatigue  
There is a multitude of fatigue measuring instruments, all based on self-report. The 
various instruments can be classified as either disease-specific or generic, and either 
multi- or uni-dimensional. For a non-exhaustive list of fatigue measuring instruments, 
see Table 3.  
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Table 3. Some of the most frequently used fatigue scales. 
Name of scale  Dimensions Comments 
Chalder Fatigue Scale (127)  Physical fatigue, mental fatigue Generic 
Fatigue Assessment Instrument 
(128) 
 Fatigue severity, situation-specific fatigue, 
fatigue consequences, responsiveness to 
sleep/rest 
 
Generic 
FIS (129)  Physical fatigue, cognitive fatigue, 
psychosocial fatigue 
Generic 
FSS (15)   Uni-dimentional Generic 
MFI-20 (130)  General fatigue, physical fatigue, mental 
fatigue, reduced motivation, reduced activity 
Generic 
The Piper Fatigue Scale (131)  Behavioral/severity, affective meaning, 
sensory and cognitive/mood 
Generic                    
Fatigue VAS  Uni-dimentional Generic 
Medical Outcomes Study Short 
Form 36 (SF-36) (132) 
 Vitality subscale assesses fatigue Generic HRQOL 
measure 
Parkinson Fatigue Scale (133)  Physical fatigue Parkinson`s 
disease 
Profile of Fatigue (134)  Somatic fatigue, mental fatigue, general 
discomfort 
PSS 
FIS, Fatigue Impact Scale; FSS, Fatigue Severity Scale; HRQOL, health-related quality of life,  MFI, 
Multidimensional Fatigue Inventory ; PSS, primary Sjøgren`s syndrome. 
 
It is currently not clear which approach is the best to measure (central) fatigue in pSS, 
and how well the different scales measure the core experience of fatigue, not 
influenced by depression or other confounders. Importantly, all scales are based on 
self-report questionnaires that each patient may interpreted differently. It is crucial 
that the instructions for filling out the scale are properly explained, and ideally the 
same person should administer the scale to all patients in a study. Recall bias and 
mood at present are possible hazards to all self-report instruments. The measured 
degree and prevalence of fatigue in a (patient) population depends on the fatigue 
measuring instrument used, and results from different scales are difficult to compare. 
Wolfe compared the fatigue VAS scale with three  multidimensional fatigue 
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instruments in RA, and found that the VAS scale performed “as well as or better than 
longer scales in respect to sensitivity to change, and is  as least as well correlated 
with clinical variables as longer scales” (118). It is debated what represents the 
minimal clinically important difference for the various fatigue-scales. A statistically 
significant reduction in fatigue score is not necessarily important or even detectable 
by the patient. A common approach is to predefine the numerical reduction in fatigue 
score that is considered clinically relevant, i.e. a 15 mm reduction in fatigue VAS. But 
a 15 mm reduction may not represent the same experience for a patient who starts off 
with a fatigue VAS score of 90 and a patient with a VAS score of 30. Dass et al used 
a 20% reduction in fatigue as an outcome measure in their clinical trial of rituximab 
and fatigue in pSS in 2008 (27). We believe this is a sensitive approach to fatigue 
assessment, although in our opinion a 20% reduction in fatigue may not always be 
clinically relevant. Fatigue fluctuates over days and months, and the limitations to 
self-report scales should be taken into consideration when defining a cut-off value. 
For this reason we applied a 50% reduction in fatigue as a post hoc outcome in the 
clinical trial (Paper I). The best approach to evaluate repeated measures of fatigue is 
currently not known, but intuitively a 50% reduction in fatigue over time (half as 
much fatigue as before) seems a sensible endpoint. 
Protein oxidation  
Several biomarkers are available to assess the degree of oxidative stress in an 
organism, but there are limitations regarding their utility. Ideally a biomarker of 
oxidative stress should be able to predict the development of disease, detect a major 
part of the oxidised target, be stable upon storage and not confounded by diet, and 
measured by validated technology in samples that are easily obtainable, such as blood 
and saliva (135). AOPP and PC fulfil most of the suggested criteria for an ideal 
biomarker. AOPP and PC are reportedly associated with the development of disease, 
not only autoimmune, but also cardiovascular, renal and pulmonary, Table 2 and 
(136-139). Most studies of AOPP and PC have been cross-sectional, and so a 
causative association between the biomarkers and disease has not been established. 
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Both AOPP and PC detect major parts of the oxidised protein and can be measured in 
plasma by validated analysing methods. Diet is a confounder in the assessment of 
protein-oxidation, as we have previously shown (119). It must be considered a 
limitation to Paper II that the individuals under study were not fasting when blood 
samples were drawn.  
AOPP methods have suffered from poor reproducibility and accuracy, mainly due to 
precipitation of lipids. Our group has developed an improved method for AOPP 
detection, in which plasma lipids are solubilised (119). This method has a 
significantly improved reproducibility and accuracy when compared to formerly 
published methods. We strongly encourage the use of this method in future studies. 
PC is the most frequently used measure of oxidative stress (140) and is also 
considered a reliable marker of free radical reaction intensity (141). It has a longer 
half-life  than lipid peroxidation products (142). By using two recognised markers of 
protein oxidation we have shown that oxidative stress is increased in pSS. One 
limitation to Paper II could be that we have not measured lipid or DNA oxidation, and 
not assessed the antioxidant defences. Regarding the latter, results are conflicting 
whether antioxidant capacity is reduced (depleted) or not during inflammation (135). 
We believe the chosen biomarkers of oxidative stress are valid and representative of 
the redox balance in the individual.      
Gene analysis 
We have investigated SNPs in candidate genes, based on gene expression studies in 
CFS (108, 121, 122). The candidate genes were selected in 2008, at a time when few 
studies of genetic variation and fatigue were available. In the light of recent years` 
extensive research in this area, gene selection for future studies should be based upon 
genetic associations found in expanded patient materials.  
An inherent challenge in fatigue research is the use of self-report scales. The FSS and 
VAS instruments were administered by different persons at SUS and HUS; this might 
have influenced the fatigue scoring and ultimately the grouping of patients. In Paper 
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III, dichotomizing according to VAS scores ≥/<50 classified a patient with VAS 49 as 
“low fatigue” and VAS 51 as “high fatigue”. Much information can be lost in 
dichotomising the results from continuous scales (143), however this approach was 
considered best for the associations analysis of genotype and fatigue. Other values of 
VAS or the FSS could have been used as cut-off values for dichotomisation; we 
cannot exclude the possibility that this might have altered the results. An alternative 
approach would be to exclude all patients with VAS scores between 40-60mm, to 
achieve more homogenous “high/low fatigue” populations. However, the power to 
detect an association would decrease with the smaller sample size. 
Low power is a limitation to Paper III. Power calculations in gene studies are based 
on several assumptions made prior to the analysis. Power is presented as an interval, 
which reflects the influence of MAF on power. A low MAF decreases power while a 
high MAF increases power; common variants are more likely to be detected. In 
addition to MAF and sample size, power is influenced by the genotype relative risk 
(GRR) of the SNP or loci in question. We used a conservative approach, estimating 
GRR for fatigue to be 1.2 based on the current average genotype relative risk in 
autoimmune disorders. If we expected a higher GRR, i.e. 1.5, the power to detect 
association would increase, see Table 4. The best way to increase power is to increase 
the sample size. PSS patients included in Paper III were recruited from an area 
covering almost 18% of the Norwegian population – multicentre studies are thus 
required to increase sample size further.    
These limitations are more or less specific to Paper III. However, several general 
concerns exist regarding genetic studies. As the DNA sequencing methods improve, it 
has also become evident that several rare, but important variants are not tagged by the 
commercial sequencing kits. Although the common variants are common, rare 
variants are more frequent when added together (144). Further, SNP analysis and 
GWAS do not account for genetic interactions.  There is evidence to indicate that 
gene-gene (epistasis) or gene-environment interactions contribute to complex diseases 
(145). In addition, epigenetic influence and the impact of microDNA are not 
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accounted for in these analyses. Taken together, genetic variation seems to influence 
most biological pathways and disease processes, but also holds limitations that cannot 
be overlooked.    
 
Table 4. Power calculations. 
    Power interval         
  GRR 
MAF 
0.02 
MAF 
0.5 
Prevalenc
e 
Case
s 
Control
s 
Controls:cases 
ratio 
pSS vs controls 1.2 5% 12% 0.05a 193 376 1.95 
pSS vs controls 1.5 5% 42% 0.05    
pSS+ vs 
controls 1.2 5% 10% 0.0375b 140 376 2.69 
pSS+ vs 
controls 1.5 5% 35% 0.0375    
pSS+ vs pSS- 1.2 5% 7% 0.72c 140 53 0.38 
pSS+ vs pSS- 1.5 5% 16% 0.72       
a Prevalence pSS.                                                                                                                                     
b Prevalence pSS with high fatigue (0.05x0.75).                                                                                      
c Prevalence high fatigue in this cohort.                                                                                                      
MAF, minor allele frequency; GRR, genotype relative risk; PSS, primary Sjøgren`s syndrome; 
PSS+; primary Sjøgren`s syndrome high fatigue; PSS-, primary Sjøgren`s syndrome low fatigue. 
 
6.3 Summary 
We conclude that some parts of fatigue in pSS have a biological origin. IL-1 
inhibition seems to reduce fatigue, pointing to a role of IL-1 in fatigue generation and 
signalling. This is in accordance with experimental animal and human studies. 
Inflammatory mediators such as IL-1 have an impact on behaviour, signalled through 
the CNS, and future fatigue-related research should investigate this pathway. It is an 
important observation that protein oxidation is increased in pSS, and it could have 
therapeutic implications. The consequences of increased oxidative stress in pSS are 
not clear, and should be a prioritized area of research. We did not detect an 
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association between protein oxidation and fatigue, and it is possible that our markers 
of oxidative stress have been too broad to detect such an association. In future studies 
we will focus on the oxidative regulation of transcription and gene expression. 
Increased oxidative stress may activate cellular defence mechanisms through 
“danger” signalling, ultimately leading to sickness behaviour and fatigue. It is 
exciting that we detected a trend for association between genetic variation in the 
SLC25A40 and PKN1 genes and fatigue. These genes are involved in cell-signalling 
and mitochondrial function, and could be involved in inflammatory pathways 
influencing fatigue. The results will need to be replicated, ideally in a GWAS 
focusing on fatigue in pSS.   
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8. Errata 
 
Page 34, line 3-4 should read: “The main conclusion was that “….there is great 
heterogeneity within genetic studies of fatigue in terms of sample sizes, sample 
descriptions and findings” (112).”  
Page 35, Paper I: “Interleukin-1 inhibition and fatigue in primary Sjögen`s syndrome – 
a double blind, randomised clinical trial” 
Page 43, line 1-2 should read: “A p-value of < 0.05 was considered significant in 
Paper I and II, and a p-value of ≤ 0.0015 was considered significant in Paper III due to 
multiple comparisons.” 
Page 50, Table 3 should read: “Table 4” and page 54, Table 4 should read: “Table 5”. 
Reference 11, page 56 should read “Sjögren H. Zur Kenntnis der Keratoconjunctivitis 
Sicca (Keratitis Filiformis bei Hypofunktion der Tränendrüsen) Acta Ophtalmol 
(Copenh) 1933;11(suppl. 2):1-151.” 
Page 67, line 23-30, has been removed. The lines were by mistake not deleted from the 
UiB setup, and read: “amples:) Brock, Gerald W (1994): Telecommunication Policy 
for the Information Age. From Monopoly to Competition, Cambridge Massachusetts: 
Harward University Pres. Borton, J. & Clay, E. (1986): "The African Food Crisis of 
1982-1986", Disasters, Vol. 10: 258-72. Blix, G., Hofvander, Y., & Vahiquist, B. 
(eds.) (1971): Famine: A Symposium Dealing with Nutrition and Relief Operations in 
Times of Disaster. Uppasala: Almquist & Wiksell / Swedish Nutrition Foundation.”  
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8. Supplements 
 
American-European Consensus Group Classification Criteria for 
Sjögren’s Syndrome (10) 
I. Ocular symptoms: A positive response to at least one of the following questions: 
1. Have you had daily, persistent, and troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms: A positive response to at least one of the following questions: 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrent or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular signs, that is, objective evidence of ocular involvement, defined as a positive result for at 
least one of the following two tests: 
1. Schirmer’s I test, performed without anesthesia (<5 mm in 5 minutes) 
2. Rose Bengal score or other ocular dye score (>4 according to van Bijsterveld’s 
    scoring system) 
IV. Histopathology: Focal lymphocytic sialoadenitis in minor salivary glands (obtained through 
normal-appearing mucosa) evaluated by an expert histopathologist, with a focus score >1, defined as 
a number of lymphocytic foci (adjacent to normal-appearing mucous acini and contain more than 50 
lymphocytes) per 4 mm2 of glandular tissue. 
V. Salivary gland involvement: Objective evidence of salivary gland involvement defined by a 
positive result for at least one of the following diagnostic tests: 
1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes) 
2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary, 
    or destructive pattern), without evidence of obstruction in the major ducts 
3. Salivary scintigraphy showing delayed uptake, reduced concentration, and/or  
    delayed excretion of tracer 
VI. Autoantibodies: Presence in the serum of the following autoantibodies: 
68 
1. Antibodies to Ro (SSA) or La (SSB) antigens, or both 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV  
    (Histopathology) or VI (Serology) is positive 
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, or VI) 
c. The classification tree procedure represents a valid alternative method for  
    classification, though it should be more properly used in a clinical- 
    epidemiological survey 
For secondary SS 
In patients with a potentially associated disease (for example, another well-defined connective tissue 
disease), the presence of items I or II plus any 2 from among items III, IV, and V may be considered 
as indicative of secondary SS. 
 
Exclusion criteria: 
1. Past head and neck radiation treatment 
2. Hepatitis C infection  
3. Acquired immunodeficiency syndrome (AIDS) 
4. Pre-existing lymphoma 
5. Sarcoidosis 
6. Graft versus host disease 
7. Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug) 
 
 
 
